Cargando…
The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies
Extracellular matrix metalloproteinase inducer (EMMPRIN) has been reported to be associated with tumor formation and invasion in many studies. However, the clinicopathological significance and prognosis of EMMPRIN in cancer patients remains inconclusive. Therefore, we conducted a meta-analysis to as...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669917/ https://www.ncbi.nlm.nih.gov/pubmed/29137291 http://dx.doi.org/10.18632/oncotarget.19740 |
_version_ | 1783275929397624832 |
---|---|
author | Fan, Hengwei Yi, Wanwan Wang, Chenxing Wang, Jisheng |
author_facet | Fan, Hengwei Yi, Wanwan Wang, Chenxing Wang, Jisheng |
author_sort | Fan, Hengwei |
collection | PubMed |
description | Extracellular matrix metalloproteinase inducer (EMMPRIN) has been reported to be associated with tumor formation and invasion in many studies. However, the clinicopathological significance and prognosis of EMMPRIN in cancer patients remains inconclusive. Therefore, we conducted a meta-analysis to assess the predictive potential of EMMPRIN in various cancers. By searching Pubmed, Cochrane library database and web of science comprehensively, 39studies with 5739 cases were included in our meta-analysis. The results indicated that EMMPRIN overexpression was significantly associated with poor outcome of cancers (HR=2.46, 95% CI: 2.21-2.75, P<0.0001). In addition, a significant relation was found between EMMPRIN overexpression and clinicopathological features, such as tumor stage (T3+T4/ T1+T2, OR=1.87, 95% CI:1.64-2.12, P<0.0001), tumor differentiation (poor/ well+ moderate, OR=1.09, 95% CI:1.60-2.23, P<0.0001), clinical stage (III+IV /I +II, OR=1.96, 95% CI:1.69-2.27, P<0.0001) and nodal metastasis (positive/negative, OR=2.37, 95% CI:1.93-2.90, P<0.0001). However, the expression of EMMRIN was not significantly associated with tumor stage in cervical cancer (OR=1.35, 95%CI: 0.73-2.48, P=0.33). In conclusion, EMMPRIN overxepression is significantly associated with clinicopathological characteristics and prognosis of cancers. Thus, EMMPRIN may be regarded as a promising bio-marker in predicting the clinical outcome of patients in cancers and could be used as the therapeutic target during clinical practices. |
format | Online Article Text |
id | pubmed-5669917 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-56699172017-11-09 The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies Fan, Hengwei Yi, Wanwan Wang, Chenxing Wang, Jisheng Oncotarget Research Paper Extracellular matrix metalloproteinase inducer (EMMPRIN) has been reported to be associated with tumor formation and invasion in many studies. However, the clinicopathological significance and prognosis of EMMPRIN in cancer patients remains inconclusive. Therefore, we conducted a meta-analysis to assess the predictive potential of EMMPRIN in various cancers. By searching Pubmed, Cochrane library database and web of science comprehensively, 39studies with 5739 cases were included in our meta-analysis. The results indicated that EMMPRIN overexpression was significantly associated with poor outcome of cancers (HR=2.46, 95% CI: 2.21-2.75, P<0.0001). In addition, a significant relation was found between EMMPRIN overexpression and clinicopathological features, such as tumor stage (T3+T4/ T1+T2, OR=1.87, 95% CI:1.64-2.12, P<0.0001), tumor differentiation (poor/ well+ moderate, OR=1.09, 95% CI:1.60-2.23, P<0.0001), clinical stage (III+IV /I +II, OR=1.96, 95% CI:1.69-2.27, P<0.0001) and nodal metastasis (positive/negative, OR=2.37, 95% CI:1.93-2.90, P<0.0001). However, the expression of EMMRIN was not significantly associated with tumor stage in cervical cancer (OR=1.35, 95%CI: 0.73-2.48, P=0.33). In conclusion, EMMPRIN overxepression is significantly associated with clinicopathological characteristics and prognosis of cancers. Thus, EMMPRIN may be regarded as a promising bio-marker in predicting the clinical outcome of patients in cancers and could be used as the therapeutic target during clinical practices. Impact Journals LLC 2017-07-31 /pmc/articles/PMC5669917/ /pubmed/29137291 http://dx.doi.org/10.18632/oncotarget.19740 Text en Copyright: © 2017 Fan et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Fan, Hengwei Yi, Wanwan Wang, Chenxing Wang, Jisheng The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies |
title | The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies |
title_full | The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies |
title_fullStr | The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies |
title_full_unstemmed | The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies |
title_short | The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies |
title_sort | clinicopathological significance and prognostic value of emmprin overexpression in cancers: evidence from 39 cohort studies |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669917/ https://www.ncbi.nlm.nih.gov/pubmed/29137291 http://dx.doi.org/10.18632/oncotarget.19740 |
work_keys_str_mv | AT fanhengwei theclinicopathologicalsignificanceandprognosticvalueofemmprinoverexpressionincancersevidencefrom39cohortstudies AT yiwanwan theclinicopathologicalsignificanceandprognosticvalueofemmprinoverexpressionincancersevidencefrom39cohortstudies AT wangchenxing theclinicopathologicalsignificanceandprognosticvalueofemmprinoverexpressionincancersevidencefrom39cohortstudies AT wangjisheng theclinicopathologicalsignificanceandprognosticvalueofemmprinoverexpressionincancersevidencefrom39cohortstudies AT fanhengwei clinicopathologicalsignificanceandprognosticvalueofemmprinoverexpressionincancersevidencefrom39cohortstudies AT yiwanwan clinicopathologicalsignificanceandprognosticvalueofemmprinoverexpressionincancersevidencefrom39cohortstudies AT wangchenxing clinicopathologicalsignificanceandprognosticvalueofemmprinoverexpressionincancersevidencefrom39cohortstudies AT wangjisheng clinicopathologicalsignificanceandprognosticvalueofemmprinoverexpressionincancersevidencefrom39cohortstudies |